These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

886 related articles for article (PubMed ID: 22178752)

  • 1. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.
    Dekeyne A; Brocco M; Loiseau F; Gobert A; Rivet JM; Di Cara B; Cremers TI; Flik G; Fone KC; Watson DJ; Papp M; Sharp T; Serres F; Cespuglio R; Olivier B; Chan JS; Lavielle G; Millan MJ
    J Pharmacol Exp Ther; 2012 Mar; 340(3):765-80. PubMed ID: 22178753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
    Chanrion B; Mannoury la Cour C; Gavarini S; Seimandi M; Vincent L; Pujol JF; Bockaert J; Marin P; Millan MJ
    Mol Pharmacol; 2008 Mar; 73(3):748-57. PubMed ID: 18083778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.
    Dekeyne A; Mannoury la Cour C; Gobert A; Brocco M; Lejeune F; Serres F; Sharp T; Daszuta A; Soumier A; Papp M; Rivet JM; Flik G; Cremers TI; Muller O; Lavielle G; Millan MJ
    Psychopharmacology (Berl); 2008 Sep; 199(4):549-68. PubMed ID: 18523738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT(2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats.
    Kimura Y; Naitou Y; Wanibuchi F; Yamaguchi T
    Eur J Pharmacol; 2008 Jul; 589(1-3):157-62. PubMed ID: 18582863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
    Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
    Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
    Millan MJ; Dekeyne A; Newman-Tancredi A; Cussac D; Audinot V; Milligan G; Duqueyroix D; Girardon S; Mullot J; Boutin JA; Nicolas JP; Renouard-Try A; Lacoste JM; Cordi A
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1192-205. PubMed ID: 11082457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
    Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes.
    Yonezawa A; Yoshizumi M; Ebiko M; Ise SN; Watanabe C; Mizoguchi H; Kimura Y; Sakurada S
    Pharmacol Biochem Behav; 2008 Feb; 88(4):367-73. PubMed ID: 17936345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin1A autoreceptor activation by S 15535 enhances circadian activity rhythms in hamsters: evaluation of potential interactions with serotonin2A and serotonin2C receptors.
    Gannon RL; Millan MJ
    Neuroscience; 2006; 137(1):287-99. PubMed ID: 16289351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
    Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
    Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive activity of serotonin 2C receptors at G protein-independent signaling: modulation by RNA editing and antidepressants.
    Labasque M; Meffre J; Carrat G; Becamel C; Bockaert J; Marin P
    Mol Pharmacol; 2010 Nov; 78(5):818-26. PubMed ID: 20699324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
    Harada K; Aota M; Inoue T; Matsuda R; Mihara T; Yamaji T; Ishibashi K; Matsuoka N
    Eur J Pharmacol; 2006 Dec; 553(1-3):171-84. PubMed ID: 17074317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
    J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
    Jensen NH; Rodriguiz RM; Caron MG; Wetsel WC; Rothman RB; Roth BL
    Neuropsychopharmacology; 2008 Sep; 33(10):2303-12. PubMed ID: 18059438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
    Kekewska A; Hübner H; Gmeiner P; Pertz HH
    J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.